Abstract: The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.

Abstract: Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.

Abstract: Methods for identifying compounds in the treatment of muscular dystrophies, include the use of disease relevant cells derived from a patient. Compounds identified by these methods are useful in the treatment of muscular dystrophy.

Abstract: A method of determining a likelihood of an occurrence of a cardiac arrhythmia in a patient includes receiving three-dimensional imaging data of said patient's heart, constructing a whole-heart model for simulating at least one of electrophysiological activity or electromechanical activity of the patient's heart using the three-dimensional imaging data, simulating a response of the patient's heart to each of a plurality of stimulations to a corresponding plurality of different locations within the patient's heart using the whole-heart model, classifying each simulation outcome for each stimulation as one of a normal heart rhythm or a cardiac arrhythmia, calculating a likelihood index based on results of the classifying, and determining the likelihood of the occurrence of the cardiac arrhythmia in the patient based on the likelihood index. Software and data processing systems that implement the above methods are also provided.

Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

Abstract: Methods, reporter gene constructs, and kits for using prostate-specific membrane antigen (PSMA) as an imaging reporter to image a variety of cells and tissues are provided.

Abstract: A device and method for analyzing of a disturbed pattern of pulse wave front results in a non-invasive, real-time diagnostic tool of arterial vascular performance on both a global and regional scale. The device provides a single number quantifying how well the arterial tree as a whole is coupled to receive and distribute a stroke volume of a single heartbeat. Changing heart rate, contractility, volume status, and afterload will change stroke volume and ejection time. Different vasculatures with different properties (e.g., size and intrinsic stiffness) will be best matched for different stroke volumes and ejection times to provide optimal coupling. The device will allow finding the optimal set of parameters for individual patient.

Abstract: The present invention relates to the field of pulmonary, cardiac and inflammatory disorders. More specifically, the present invention provides methods and compositions for treating disorders associated with Resistin. In a specific embodiment, the present invention provides an antibody that binds human Resistin.

Abstract: A method is provided. The method is executable by a processor of a battery management system. The method includes sending a first command signal to a multiplexer to cause the multiplexer to select a cell of a battery. The method also includes sending a second command signal to a current source to apply a current to the cell of the battery. The method also includes receiving measurement information based on the application of the current to the cell from a measurement circuit.

Abstract: Methods, system, and media for identifying one or more ablation locations in an atrial tissue region in an atrial fibrillation (AF) patient with atrial fibrosis are disclosed. Three-dimensional imaging data representing the atria of the patient may be received. A patient-specific model of the atria may be generated from the three-dimensional imaging data. Simulation of the AF on the patient-specific model may be conducted to identify AF-perpetrating regions. One or more ablation locations in the atria may be identified from the AF-perpetrating regions.

Abstract: Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.

Abstract: The present invention is directed to embodiments of reactive material (RM) and an associated chemical time delay that includes an RM, according to an embodiment of the present invention. One embodiment includes a delay material that is an RM patterned on a substrate using lithographic techniques. Another embodiment includes a delay material that is an RM deposited on a patterned substrate such as a mesh. The present invention also includes a chemical time delay that includes either embodiment of the delay material, or any variation on the delay material that would be known to or conceivable to one of skill in the art.

Abstract: The present inventors discovered that the molecule pyridinylthiazolamine (PTA) specifically prevents the protein-protein interaction of hLC3 with hAtg3 in vitro and in cell based assays. The inventors have developed a novel class of PTA analogs which also prevents the protein-protein interaction of hLC3 with hAtg3 in vitro, and in cell based assays, and which can be used in prior to, or in combination with chemotherapeutic agents to treat proliferative diseases such as cancer.

Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

Abstract: Methods and systems for enabling human-machine collaborations include a generalizable framework that supports dynamic adaptation and reuse of robotic capability representations and human-machine collaborative behaviors. Specifically, a method of feedback-enabled user-robot collaboration includes obtaining a robot capability that models a robot's functionality for performing task actions, specializing the robot capability with an information kernel that encapsulates task-related parameters associated with the task actions, and providing an instance of the specialized robot capability as a robot capability element that controls the robot's functionality based on the task-related parameters.

Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

Abstract: An ultrasound imaging system having real-time tracking and image registration includes a fiducial-marker system comprising an ultrasound transmitter structured to provide a localized ultrasound pulse at an optically observable localized spot on a body of interest. The system further includes an optical imaging system, a two-dimensional ultrasound imaging system, an optical image processing system, and an ultrasound image processing system.

Abstract: In some aspects, the invention relates to methods for determining the proportion of intact, hypermutated, deleted, and/or defective proviruses in a sample of nucleic acids, e.g., a sample obtained from a subject. The subject may be a human subject. The virus may be HIV.

Abstract: A method for facilitating real time tracking of an airborne asset via downlink of GPS signals that are usable for determining asset location information from the asset to a ground station may include receiving a first GPS signal and a second GPS signal at a device disposed on the airborne asset and combining the first and second GPS signals to form combined signal responsive to filtration and amplification of the first and second GPS signals. The method may further include employing an overlay analog translation to convert the combined signal into a composite signal at a different frequency than the combined signal, generating a pilot carrier frequency for association with the composite signal, and amplifying the composite signal prior to transmission via the downlink from the airborne asset to the ground station. The pilot carrier frequency and amplitude may be adjustable.